Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by SouthernTierTomon Jan 18, 2021 11:13am
261 Views
Post# 32319725

RE: The "O" word...the options are coming!

RE: The "O" word...the options are coming!C'mon fellas, let's get these options doled out and get on with the program.

Typically the firm grants options in late January or early February.

"Clearly" ( throat clear ), the US was not impressed by the massive IR program of last week ; - (

I say we reach out to Asia and the EU and figure out exactly what they are doing to be so beneficial in the CV19 battle.  The Euphas2 registry is simply an expansion of the rather stunning ( BUT not all related to EDT ) results of the original Euphas phase II trial in Italy.

I figure the FDA would NOT have allowed / added a third CV19 site to our exisiting CV19 trial if the results from Stony Brook and George Harrison were "futile"..."My sweet lord"...it's time to amp up the fight against CV19...especially when we have the products that back in March appeares to be "so helpful" ??
<< Previous
Bullboard Posts
Next >>